Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
Francis KE, Simon S, Gebski V, Joly F, Ledermann JA, Penson RT, Oza AM, Korach J, Lainez N, Cecere SC, Tasca G, Gropp-Meier M, Fujiwara K, Lowe ES, Friedlander M, Pujade-Lauraine E, Lee CK. Francis KE, et al. Among authors: cecere sc. Gynecol Oncol. 2024 Nov 12;192:50-55. doi: 10.1016/j.ygyno.2024.11.004. Online ahead of print. Gynecol Oncol. 2024. PMID: 39536691 Free article.
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.
Sehouli J, Boer J, Brand AH, Oza AM, O'Donnell J, Bennett K, Glaspool R, Lee CK, Ethier JL, Harter P, Seebacher-Shariat V, Chang TC, Cohen PA, van Gorp T, Chavez-Blanco A, Welch S, Hranovska H, O'Toole S, Lok CAR, Madariaga A, Rauh-Hain JA, Perez Fidalgo A, Tan D, Michels J, Pothuri B, Fujiwara N, Rosengarten O, Nishio H, Kim SI, Mukopadhyay A, Piovano E, Cecere SC, Kohn EC, Mukherjee U, Nasser S, Lindemann K, Croke J, Chen X, Geissler F, Bookman MA. Sehouli J, et al. Among authors: cecere sc. Int J Gynecol Cancer. 2024 Nov 4;34(11):1677-1684. doi: 10.1136/ijgc-2024-005982. Int J Gynecol Cancer. 2024. PMID: 39496422
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Among authors: cecere sc. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I; PAOLA-1/ENGOT-ov25 investigators. Harter P, et al. Among authors: cecere sc. Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.10.828. Online ahead of print. Ann Oncol. 2024. PMID: 39528049 Free article.
Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options.
Forte M, Cecere SC, Di Napoli M, Ventriglia J, Tambaro R, Rossetti S, Passarelli A, Casartelli C, Rauso M, Alberico G, Mignogna C, Fiore F, Setola SV, Troiani T, Pignata S, Pisano C. Forte M, et al. Among authors: cecere sc. Crit Rev Oncol Hematol. 2024 Oct 22;204:104533. doi: 10.1016/j.critrevonc.2024.104533. Online ahead of print. Crit Rev Oncol Hematol. 2024. PMID: 39442900 Review.
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.
Haggstrom L, Lee YC, Scott C, Harter P, Woelber L, Ledermann J, Gourley C, McNeish IA, Amant F, Ray-Coquard I, Leary A, Oza AM, Tinker A, González Martin A, Cecere SC, Pignata S, Colombo N, Yoshida H, Marth C, Rosengarten O, Moore KN, Gómez-García EM, Tan D, Friedlander ML. Haggstrom L, et al. Among authors: cecere sc. Int J Gynecol Cancer. 2024 Oct 22:ijgc-2024-005976. doi: 10.1136/ijgc-2024-005976. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 39438068
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
Bignotti E, Simeon V, Ardighieri L, Kuhn E, Marchini S, Califano D, Cecere SC, Bugatti M, Spina A, Scognamiglio G, Paracchini L, Russo D, Arenare L, Tognon G, Lorusso D, Beltrame L, D'Incalci M, Sartori E, De Censi A, Odicino F, Perrone F, Chiodini P, Pignata S. Bignotti E, et al. Among authors: cecere sc. Int J Cancer. 2024 Oct 16. doi: 10.1002/ijc.35203. Online ahead of print. Int J Cancer. 2024. PMID: 39415516
CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization.
Portella L, Bertolini G, Guardascione G, Di Febbraro DG, Ieranò C, D'Alterio C, Rea G, Napolitano M, Santagata S, Trotta AM, Camerlingo R, Scarpa E, Cecere SC, Ottaiano A, Palumbo G, Morabito A, Somma T, De Rosa G, Mayol L, Pacelli R, Pignata S, Scala S. Portella L, et al. Among authors: cecere sc. Heliyon. 2024 Jul 31;10(15):e35524. doi: 10.1016/j.heliyon.2024.e35524. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170328 Free PMC article.
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.
Coleman RL, Lorusso D, Oaknin A, Cecere SC, Denys H, Colombo N, van Gorp T, Konner JA, Romeo Marin M, Harter P, Murphy C, Wang Y, Esteves B, Method M, Matulonis U. Coleman RL, et al. Among authors: cecere sc. Int J Gynecol Cancer. 2024 Aug 5;34(8):1119-1125. doi: 10.1136/ijgc-2024-005401. Int J Gynecol Cancer. 2024. PMID: 38858103 Free PMC article. Clinical Trial.
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
Roma C, Esposito Abate R, Sacco A, Califano D, Arenare L, Bergantino F, Pisano C, Cecere SC, Scambia G, Lorusso D, Artioli G, Tasca G, Spina A, Russo D, Gadducci A, De Angelis C, Bologna A, Marchini S, Capoluongo ED, Perrone F, Pignata S, Normanno N. Roma C, et al. Among authors: cecere sc. Eur J Cancer. 2024 Jul;206:114127. doi: 10.1016/j.ejca.2024.114127. Epub 2024 May 23. Eur J Cancer. 2024. PMID: 38797038
72 results